Keyphrases
Tuberculosis
100%
Multidrug-resistant Tuberculosis (MDR-TB)
83%
India
70%
Tuberculosis Treatment
55%
Mumbai
54%
Drug Susceptibility Testing
54%
Mycobacterium Tuberculosis (M. tb)
45%
Pediatric Tuberculosis
41%
Tertiary Care Hospital
41%
COVID-19
41%
Tuberculosis Patients
39%
Linezolid
36%
Tuberculosis Diagnosis
34%
Indian children
34%
Treatment Response
32%
Pharmacokinetics
31%
Confidence Interval
31%
HIV Infection
27%
Linezolid Resistance
27%
Tuberculosis Disease
25%
Rifampin
25%
Active Tuberculosis
23%
Household Contacts
23%
Tuberculosis Regimen
22%
Whole Genome Sequencing
21%
Body Mass Index
20%
Drug Resistance
20%
Rifampicin Resistance
18%
Treatment Initiation
17%
Bolivia
17%
Chagas Disease
17%
Treatment Regimen
16%
Infectious Diseases
16%
New Regimen
16%
Tuberculosis Treatment Outcomes
16%
Bedaquiline
16%
Sputum
15%
Xpert MTB
15%
Drug Resistance mutations
15%
Delamanid
15%
Epidemiology
15%
Odds Ratio
15%
Clinical Laboratory
14%
Fluoroquinolones
14%
Low-middle Income Countries
13%
Insured Population
13%
Tuberculous Meningitis
13%
Short Course
13%
Transcriptomics
13%
Emtricitabine
13%
Medicine and Dentistry
Infection
61%
Multidrug Resistant Tuberculosis
57%
Mycobacterium Tuberculosis
57%
Outpatient
56%
Tertiary Care
56%
Linezolid
54%
Human Immunodeficiency Virus
54%
Disease
54%
Severe Acute Respiratory Syndrome Coronavirus 2
45%
Drug Sensitivity
39%
Diarrhea
30%
COVID-19
30%
Household
29%
Cohort Effect
28%
Sputum
28%
Next Generation Sequencing
27%
Pediatrics
27%
Human Immunodeficiency Virus Infection
27%
Drug Resistance
23%
Symptom
23%
Quinolone Derivative
23%
Tuberculosis
22%
Tuberculosis Treatment
22%
Diagnosis
21%
Body Mass Index
21%
Rifampicin
19%
Public Health
19%
Disease Burden
18%
Chagas Disease
17%
Bedaquiline
16%
Moxifloxacin
15%
Epileptic Absence
15%
Odds Ratio
15%
Patient Referral
15%
Clinical Feature
14%
Low and Middle Income Countries
13%
Transcriptomics
13%
Rotavirus
13%
Cost-Effectiveness Analysis
13%
Chronic Disease
13%
Mycobacterium Avium-Intracellulare Infection
13%
Nervous System
13%
Plastic Surgery Procedure
13%
Drug Hypersensitivity
13%
Treatment Response
13%
Disease Course
13%
Mental Health Care
13%
Aspergillosis
13%
Coronavirinae
13%
Pretomanid
13%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
93%
Multi-Drug-Resistant Tuberculosis
67%
HIV
52%
Infection
45%
Pharmacokinetics
43%
Coronavirinae
41%
Linezolid
41%
Symptom
38%
SARS Coronavirus
33%
Diarrhea
30%
Quinolone Derivative
29%
Bedaquiline
28%
Human Immunodeficiency Virus Infection
27%
Mycobacterium Tuberculosis
22%
Rifampicin
21%
Respiratory Tract
18%
Moxifloxacin
18%
Isoniazid Plus Rifampicin
17%
Drug Resistance
17%
Chagas Disease
17%
Epileptic Absence
15%
Vaccination Policy
15%
Clinical Feature
14%
Tuberculous Meningitis
13%
Emtricitabine
13%
Rotavirus
13%
Pretomanid
13%
Dolutegravir
13%
Chronic Disease
13%
Delamanid
13%
Disease Course
13%
Tenofovir
13%
Extensively Drug-Resistant Tuberculosis
13%
Recurrent Disease
13%
Prospective Cohort Study
13%
Myalgia
13%
Diabetes Mellitus
13%
Tenofovir Alafenamide
13%
Chagas Cardiomyopathy
13%
Prevalence
12%
Virus RNA
12%
Tuberculosis
9%
Congestive Heart Failure
6%
Obesity
6%
Drug Resistant Tuberculosis
5%
Streptomycin
5%
End Stage Renal Disease
5%
Cohort Study
5%
Side Effect
5%